29 Placebo W9 Live Acoustic 23 09 2006

Placebo Centrefolds

Directed by Valentin Korniyko, Actress Olga Storozhuk, DOP Alexander Boyko, Idea ... Made in Kiev. Non-official video for Placebo's Centrefolds.

Placebo-daddy cool (party)

полезные советы. Комментарии : LiveInternet - Российский Сервис ...

≪a href="http://www.liveinternet.ru/users/pretenditdidnothurt/post146730070/">РРРРРРСР СРРРСС</a><br/>РРРСР 200 РСРРР РСРСРРРР СССРРР РРёРР РРСРР СРРР. ССР РРРРРРС РРР РСССР СРРСС. РРС РРРСРРР СРРСРС РСРРР РР СРРёСР. РРР СРСРСР РР РРРР РРРёСРС. СРРРР РРРРР РРРСРРСС СРРРР РССРРРё РёРРё РРСРРССРСС, РРР РРРССРёРС РРССРё СРРРС СРРС Р РРСРРРР. ССС СРСС-РС РРРССР РРРСРС, СРР Р РРСРР ССРСРРРРёРё....<br><a href="http://www.liveinternet.ru/users/pretenditdidnothurt/post146730070/">РСРёРРёРРР РРРРёСРё

...

Читать дальше...

TRACER: Vorapaxar failed to reduce death, MI, stroke risks

22.05.12 - Cardiology Today

. Harrington reports significant research grants and is a consultant/advisory board member for Merck. Dr. Interestingly, bleeding continues over time and 80% of intracranial hemorrhage bleeds are beyond 4 months. The risk vs. Disclosure: The TRACER trial was funded by Merck. More than half [of events] were in first 4 months. . My interpretation is that the placebo study population had a clinically important event rate that was not just the result just of an underpowered studyв it had events. benefit was not worthwhile in the tested dose and study population, as designed here. If you consider the primary endpoint, I would argue that the addition of softer components to the primary endpoint is just added noise. The potential remains to reduce thrombotic events, but I would argue that TRACER has missed the вsweet spotв between efficacy and safety. The potential remains to reduce thrombotic events, but I would argue that TRACER has missed the вsweet spotв between efficacy and safety.

Источник: Cardiology Today